Shares in IFA.T are down 59.5% from their 52 week high early in 2021. Company management have announced fiscal year ending Sept 31 guidance in the range of $19.5-million to $20-million compared to $11.5-million in fiscal 2020, representing an increase of approximately 70 per cent. Fourth-Quarter revenues (unaudited) guidance of approximately $5-million compared to $3.6-million in fiscal 2020, representing an increase of about 40 per cent. The stock has likely been subjected to tax loss selling, the pummeling of shares in companies with any connection to the covid trade, and the general bear market in microcaps stocks. This combination of circumstances has the IFA shares trading at 52 week lows. The company maintains a very solid balance sheet and strong revenue growth. We view current prices as a very strong risk/reward opportunity and feel it is a great candidate for a Santa Claus rally in the new year. We believe this high growth company offers very strong upside from current levels.
Immunoprecise Antibidodies (TSX.V: IPA) Price - $7.38 Market Cap - $143M
- ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2022
- Revenue of $4.7M
- Gross profit of $2.57M
- Invested $2.8 million in strategic research and development costs
- Adj. EBITDA loss of ($2.9M)
- Net loss of ($5M)
- Press Release https://tinyurl.com/mth8dtd8
Covid case counts continue to increase and some countries are registering record case numbers due partly to the new Omicron variant. While hospitalization numbers are not as high as earlier waves concerns are starting to mount that the sheer rate of Omicron infections could overwhelm health systems. Covid restrictions are increasing in many areas in hopes to prevent further surges in case count. A number of existing therapeutics have shown weaker or no efficacy against Omicron. This may increase the spotlight on companies like IPA who may have novel therapeutics to fight this variant of concern. We expect January to be a busy month for data and news from ImmunoPrecise.
- Aurora Solar Technologies Announces Major Customer Acceptance and New Patents for Its DM Measurement Products
- Press Release https://tinyurl.com/3as98mm9
CEMATRIX Corporation (TSX.V: CVX) Price - $0.32 Market Cap - $43M
Covalon Technologies (TSX.V: COV) Price - $2.52 Market Cap - $65M
- Covalon Announces Strong Year End and Fourth Quarter Results for Fiscal 2021
- FY Revenue of $19.5M
- FY Gross profit of $9.69M
- FY Net income of $418K
- Q4 Revenue $6.6M
- Q4 Gross profit of $3M
- Q4 Net income of $1M
- Q4 Adj. EBITDA of $1.8M
- Press Release https://tinyurl.com/363sfdhk
Crescita Therapeutics (TSX.V: CTX) Price - $0.68 Market Cap - $14M
IBEX Technologies (TSX.V: IBT) Price - $0.485 Market Cap - $12M
- IBEX Reports Results for the First Quarter Ended October 31, 2021
- Revenue of $1.78M
- EBITDA of $763K
- Net income of $664K
- Press Release https://tinyurl.com/zfyfj44d
Nova Leap Health (TSX.V: NLH) Price - $0.61 Market Cap - $48M
- Nova Leap Health Corp. Continues U.S. Expansion With Closing of Strategic Acquisition in the Midwest
- Press Release https://tinyurl.com/yeryycs2
Snipp Interactive (TSX.V: SPN) Price - $0.245 Market Cap - 58M
- Top 5 Most Valuable Food Brand Company in The Fortune 250 Signs 3rd Six Figure Contract With Snipp This Year
- Press Release https://tinyurl.com/4ys65xb5
- Snipp Interactive Inc. Executes Second Set Of Orders With Top 5 US Technology Company In The Fortune 50; 15 Country Deployment Contracted For 2022
- Press Release https://tinyurl.com/mr4smtzh
Urbanimmersive (TSX.V: UI) Price - $0.78 Market Cap - $25M
Alphinat (TSX.V: NPA) Price - $0.07 Market Cap - $4.4M
- Alphinat Announces a Profit of $91,928 for Fiscal Year Ended August 31, 2021
- Q4 Revenue of $342K
- Q4 Net loss of ($34K)
- FY Revenue $1.55M
- FY Net income of $91K
- Press Release https://tinyurl.com/2p8cfph9
